US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Drug Discovery: market research reports

RSS Feeds

Drug Discovery market research reports and industry analysis

1    3    5  6  7  8  9  10  
OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017
3/27/2014 | published by: GlobalData
... report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the pancreatic cancer market with coverage of both the early stage resectable and advanced settings. Celgene’s Abraxane was launched in the ...  |  read more...
$5,995.00
EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022
3/27/2014 | published by: GlobalData
... throughout the world. Ankylosing spondylitis primarily affects the spine and sacroiliac joints, with involvement with other joints in the shoulders, hips, and knees. It can progress into severe inflammation that fuses the spine, leading to ...  |  read more...
$3,995.00
Liver Cancer Drug Pathway Analyzer 2014
3/25/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of liver cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 173 drug targets that are included in this drug-pathway analyzing ...  |  read more...
$3,747.50
Peptides in Oncology: Drug Pathway Analyzer 2014
3/25/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of more than 74 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 183 drug targets that are included ...  |  read more...
$5,622.50
Gastrointestinal Cancer Drug Pathway Analyzer 2014
3/25/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of gastrointestinal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 134 drug targets that are included in this drug-pathway analyzing ...  |  read more...
$5,622.50
Analytical Tool - Leukemia
3/25/2014 | published by: BioSeeker Group AB
... time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current ...  |  read more...
$11,625.00
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... 366 Alpha6Beta4 integrin pathway targeting drugs in 1258 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 164 drugs. ...  |  read more...
$5,622.50
Angiogenesis in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... number of ceased drugs over the last years amount to another 173 drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs ...  |  read more...
$5,622.50
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 214 companies plus ...  |  read more...
$5,622.50
Brain Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ...  |  read more...
$5,622.50
Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... suspended drug and the accumulated number of ceased drugs over the last years amount to another 101 drugs. Calcium Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis ...  |  read more...
$5,622.50
Cell Cycle Targeting in Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... suspended drugs and the accumulated number of ceased drugs over the last years amount to another 108 drugs. Cell Cycle Targeting In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis ...  |  read more...
$5,622.50
Conjugated Drugs in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... targeting, the clinical application of ADCs is accelerating rapidly. But antibodies are not the only kind of compound one could conjugate small molecules to, nor the only class of compounds which one can yield targeted ...  |  read more...
$5,622.50
Cytokine Therapy in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 7 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
$3,747.50
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 304 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
$5,622.50
Epigenetic Therapy in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... autoimmunity, diabetes, or neurological disorders. Recent research has identified the set of enzymes and chromatin-binding proteins responsible for regulating chromatin structure. These enzymes and binding proteins form the cell’s toolkit for epigenetic regulation by opening ...  |  read more...
$3,747.50
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces ...  |  read more...
$5,622.50
FSH Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... FSH signaling which continues further downstream. Activation of PKA leads to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity ...  |  read more...
$5,622.50
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... drugs in 1260 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 146 drugs. Il-2 Signaling Pathway In Oncology ...  |  read more...
$5,622.50
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... 642 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 64 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
$5,622.50
Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. There are today 366 companies plus partners developing 566 cytokine-cytokine receptor interaction ...  |  read more...
$5,622.50
Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. There are today 247 companies plus ...  |  read more...
$5,622.50
Leukemia Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 126 drugs. Leukemia Drug Pipeline Update lists all drugs and gives ...  |  read more...
$5,622.50
Lung Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe ...  |  read more...
$5,622.50
Lymphoma Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 107 drugs. Lymphoma Drug Pipeline Update lists all drugs and gives you ...  |  read more...
$5,622.50
1    3    5  6  7  8  9  10  
 
Our Clients